FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approves a supplemental application for XELJANZ XR (tofacitinib) from Pfizer, introducing the extended-release formulation. Submission status: AP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• XELJANZ XR (tofacitinib)

Snippet

SUPPL AP for XELJANZ XR (TOFACITINIB)